Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PEPG
STRONG SELLPepGen Inc. · Healthcare · United States · $133M · Avg Vol: $2M/d
COMPANY DESCRIPTION
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular diseases, including Duchenne muscular dystrophy. Its proprietary Enhanced Delivery Oligonucleotide (EDO) platform aims to improve the intracellular delivery of therapies. The company's competitive advantage lies in its innovative drug delivery technology designed to overcome existing limitations in RNA-based therapeutics.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.00 | -1.14 | -1.34 | -2.12 | — | -1.43 | -1.14 | -1.23 | — |
| Shares | 69.2M | 69.2M | 69.2M | 68.9M | -0.4% | 69.2M | — | — | — |
| Debt | 24.5M | 20.1M | 18.7M | 17.0M | -11.5% | 16.6M | — | — | — |
| Equity | 179.6M | 108.4M | 118.6M | 147.4M | -6.4% | — | — | — | — |
| Op CF | -59.3M | -69.0M | -82.4M | -81.6M | — | -77.1M | — | — | — |
| Inv CF | -3.8M | -32.0M | -37.7M | -15.2M | — | — | — | — | — |
| Fin CF | 112.2M | -0.2M | 88.7M | 108.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PEPG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PEPG | PepGen Inc.(you) | $133M | 9 | STRONG SELL |
| AARD | Aardvark Therapeutics, Inc. | $138M | 10 | STRONG SELL |
| CBUS | Cibus, Inc. | $138M | 11 | STRONG SELL |
| CDXS | Codexis, Inc. | $135M | 12 | STRONG SELL |
| GNLX | Genelux Corporation | $130M | 7 | STRONG SELL |
| CNTB | Connect Biopharma Holdings Limited | $135M | 13 | STRONG SELL |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $164M | 9 | STRONG SELL |
| 0HIY.L | Atara Biotherapeutics, Inc. | $161M | 10 | STRONG SELL |
| KRRO | Korro Bio, Inc. | $153M | 12 | STRONG SELL |
| VANI | Vivani Medical, Inc. | $110M | 11 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%